Removal of citrate from PAS‐III additive solution improves functional and biochemical characteristics of buffy‐coat platelet concentrates stored for 7 days, with or without INTERCEPT pathogen reduction

Transfusion ◽  
2021 ◽  
Author(s):  
Hervé Isola ◽  
Catherine Ravanat ◽  
Floriane Rudwill ◽  
Anais Pongerard ◽  
Delphine Haas ◽  
...  
Keyword(s):  
Buffy Coat ◽  
Platelet Concentrates ◽  
Biochemical Characteristics ◽  
Pathogen Reduction ◽  
Additive Solution

Pathogen reduction treatment of buffy coat platelet concentrates in additive solution induces proapoptotic signaling

Transfusion ◽  
2012 ◽  
Vol 52 (10) ◽  
pp. 2094-2103 ◽  
Author(s):  
Samantha Reid ◽  
Lacey Johnson ◽  
Narelle Woodland ◽  
Denese C. Marks
Keyword(s):  
Buffy Coat ◽  
Platelet Concentrates ◽  
Reduction Treatment ◽  
Pathogen Reduction ◽  
Additive Solution

Pathogen reduction treatment alters the immunomodulatory capacity of buffy coat-derived platelet concentrates

Transfusion ◽  
2013 ◽  
Vol 54 (3) ◽  
pp. 577-584 ◽  
Author(s):  
Yen S. Loh ◽  
Lacey Johnson ◽  
Matthew Kwok ◽  
Denese C. Marks
Keyword(s):  
Buffy Coat ◽  
Platelet Concentrates ◽  
Reduction Treatment ◽  
Immunomodulatory Capacity ◽  
Pathogen Reduction

Leucocyte-Reduced Buffy Coat Platelet Concentrates (BCPC) Treated with INTERCEPT™ Stored up to 7 Days: Hemostatic Function in a Whole Blood Flow System.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 956-956
Author(s):  
Miguel Lozano ◽  
Ana Galan ◽  
Roberto Mazzara ◽  
Laurence Corash ◽  
Gines Escolar
Keyword(s):  
Blood Flow ◽  
Platelet Count ◽  
Whole Blood ◽  
Flow System ◽  
Ex Vivo ◽  
Buffy Coat ◽  
Platelet Concentrates ◽  
Platelet Storage ◽  
Pre Treatment ◽  
Additive Solution

Abstract Background: The risk of bacterial growth has limited the shelf life of platelet concentrates (PC) to 5 days. Modern platelet storage containers facilitate storage for up to 7 days, if bacterial contamination is prevented. INTERCEPT (Baxter, La Chatre, France; Cerus, Concord, CA) photochemical treatment (PCT) for pathogen reduction based on amotosalen (150μM) and UVA illumination (3 J/cm2) inactivates high titers of bacteria in PC (Transfusion2004; 44: 1496–1504). Adhesion and aggregation of platelets to injured vascular surfaces are critical aspects of platelet hemostatic function. In this study, the adhesion and aggregation of leucocyte-reduced buffy coat derived PC (BCPC), treated with INTERCEPT and stored up to 7 days, were measured on injured vascular surfaces using an ex-vivo blood flow system. Methods: BCPC were prepared from 450 mL-whole blood donations with the top and bottom method (Optipress II, Baxter). Five BCPC, of the same ABO group, were pooled with additive solution (Intersol™) the day following collection, after viral screening testing was completed. Following centrifugation and leukocyte depletion, two BCPC pools of the same ABO group were mixed and divided. One pooled BCPC was treated with INTERCEPT (I-BCPC) and the other was prepared by conventional methods (C-BCPC); and both were stored in 1.3 liter PL2410 plastic containers (Baxter R4R7012) at 22 ± 2°C with continuous agitation for 7 days. Samples for hemostatic function testing were taken immediately after preparation before splitting for treatment and after 5 and 7 days of storage. Platelet counts were performed in K3EDTA in a Coulter MD II counter (Coulter, Miami, FL). Samples of I-BCPC and C-BCPC were added to citrate anticoagulated blood, previously depleted of platelets and leukocytes by filtration, and adjusted to a final platelet count of 150x109/L. Enzymatically denuded vascular segments were exposed to circulating whole blood, reconstituted with I-BCPC and C-BCPC, in Baumgartner chambers at a shear rate of 800 s−1 for 10 minutes. The proportion (%) of the vascular surface area covered by platelets after perfusion was measured for each type of BCPC (N = 9) at each storage time point. Platelets and groups of platelets were classified as adhesive when platelet masses were less than 5 μm in height and as thrombi when height exceeded 5 μm. Data were analyzed with the SPSS 12.0.1 statistical package with significance at p < 0.05, and expressed at the mean ± SEM Results(Table). Conclusion: The platelet count of I- BCPC decreased by 12.3% including PCT processing losses and 7 days of storage. However, I- BCPC platelet adhesive and aggregatory capacities under flow conditions were similar to C- BCPC, and were well conserved for up to 7 days of storage. Hemostatic Function of Stored I-BCPC and C-BCPC Parameter I-BCPC C-BCPC p Day 1(Pre Treatment) Platelet Count (109/L) 945±40 945±40 Platelet Coverage (%) 26.0±3.7 26.0±4.2 Adhesion(%) 24.0±3.7 24.0±3.7 Thrombus(%) 1.9±0.6 1.9±0.6 Day 5 Storage Platelet Count (109/L 844±41 902±44 0.004 Platelet Coverage (%) 20.9±2.2 20.6±1.6 0.9 Adhesion(%) 19.9±2.1 19.3±1.4 0.8 Thrombus(%) 0.9±0.3 1.2±0.4 0.5 Day 7 Storage Platelet Count (109/L) 829±32 923±48 0.008 Platelet Coverage (%) 27.1±2.9 21.2±2.8 0.06 Adhesion(%) 26.0±2.7 20.4±2.7 0.06 Thrombus(%) 1.2±0.3 0.7±0.2 0.16

In vitro cell quality of buffy coat platelets in additive solution treated with pathogen reduction technology

Transfusion ◽  
2010 ◽  
Vol 50 (10) ◽  
pp. 2210-2219 ◽  
Author(s):  
Sisse R. Ostrowski ◽  
Louise Bochsen ◽  
José A. Salado-Jimena ◽  
Henrik Ullum ◽  
Inge Reynaerts ◽  
...  
Keyword(s):  
Buffy Coat ◽  
Solution Treated ◽  
Pathogen Reduction ◽  
Additive Solution

Systems analysis of metabolism in platelet concentrates during storage in platelet additive solution

2018 ◽  
Vol 475 (13) ◽  
pp. 2225-2240 ◽  
Author(s):  
Freyr Jóhannsson ◽  
Steinn Guðmundsson ◽  
Giuseppe Paglia ◽  
Sveinn Guðmundsson ◽  
Bernhard Palsson ◽  
...  
Keyword(s):  
Metabolic Model ◽  
Central Carbon Metabolism ◽  
Buffy Coat ◽  
Platelet Concentrates ◽  
Metabolomics Data ◽  
Storage Lesion ◽  
Metabolic Network Analysis ◽  
Blood Banks ◽  
Additive Solution ◽  
Collection Methods

Platelets (PLTs) deteriorate over time when stored within blood banks through a biological process known as PLT storage lesion (PSL). Here, we describe the refinement of the biochemical model of PLT metabolism, iAT-PLT-636, and its application to describe and investigate changes in metabolism during PLT storage. Changes in extracellular acetate and citrate were measured in buffy coat and apheresis PLT units over 10 days of storage in the PLT additive solution T-Sol. Metabolic network analysis of these data was performed alongside our prior metabolomics data to describe the metabolism of fresh (days 1–3), intermediate (days 4–6), and expired (days 7–10) PLTs. Changes in metabolism were studied by comparing metabolic model flux predictions of iAT-PLT-636 between stages and between collection methods. Extracellular acetate and glucose contribute most to central carbon metabolism in PLTs. The anticoagulant citrate is metabolized in apheresis-stored PLTs and is converted into aconitate and, to a lesser degree, malate. The consumption of nutrients changes during storage and reflects altered PLT activation profiles following their collection. Irrespective of the collection method, a slowdown in oxidative phosphorylation takes place, consistent with mitochondrial dysfunction during PSL. Finally, the main contributors to intracellular ammonium and NADPH are highlighted. Future optimization of flux through these pathways provides opportunities to address intracellular pH changes and reactive oxygen species, which are both of importance to PSL. The metabolic models provide descriptions of PLT metabolism at steady state and represent a platform for future PLT metabolic research.

scholarly journals Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction

2010 ◽  
pp. no-no ◽  
Author(s):  
Jean-Louis H. Kerkhoffs ◽  
Wim L. J. Van Putten ◽  
Viera M. J. Novotny ◽  
Peter A.W. Te Boekhorst ◽  
Martin R. Schipperus ◽  
...  
Keyword(s):  
Clinical Effectiveness ◽  
Platelet Concentrates ◽  
Pathogen Reduction ◽  
Additive Solution

scholarly journals Extended storage of buffy coat platelet concentrates in plasma or a platelet additive solution

Transfusion ◽  
2014 ◽  
Vol 54 (9) ◽  
pp. 2283-2291 ◽  
Author(s):  
Sherrill J. Slichter ◽  
Doug Bolgiano ◽  
Jill Corson ◽  
Mary Kay Jones ◽  
Todd Christoffel ◽  
...  
Keyword(s):  
Buffy Coat ◽  
Platelet Concentrates ◽  
Additive Solution
Sign in / Sign up

Export Citation Format

Share Document